GovChime
AWARDDEFINITIVE CONTRACTSmall business

Definitive contract HHSN272201700011CCHRYSALIS BIOTHERAPEUTICS, INC.

Overview

Award facts

Net obligations
$6.95M
$6,954,509of $6.95M potential value
Outlays (paid to date)
$1.50M
$1.50M paid of $6.95M obligated$1,500,152
Period of performance
Jan 30, 2017 to Aug 31, 2021
Ended
Modifications
17
Latest action Apr 5, 2023
Contract type
Definitive contract
PIID HHSN272201700011C

Contract value is the most the government could spend; obligations are what it has legally committed; outlays are what it has actually paid.

Description of requirement

IGF::OT::IGF TP508: A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION

Dates and value

Award date
Signed on Jan 30, 2017
Potential end of performance
Aug 30, 2021
Current value
$6,954,509Base and exercised options
Potential value (if all options are exercised)
$6,954,509

Obligations by fiscal year of action

  • FY2023: -$0 (de-obligation)
  • FY2020: $1,500,152
  • FY2019: $1,864,898
  • FY2018: $1,984,084
  • FY2017: $1,605,375

Total across 5 fiscal years: $6,954,509

Net de-obligation in that fiscal year (obligations withdrawn).

Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Apr 5, 2023. View on USAspending · Recipient on SAM.gov

Recipient

LocationGALVESTON, TX
UEIXW1VFGGRLDW3
CAGE code5DAY4
Business sizeSmall businessSize at award, per the contracting officer
Organization typeCorporate not tax exempt

Business types and certifications

For-profit organizationCorporation (not tax-exempt)

As represented in SAM.gov at the time of the action.

Subcontracting network

The prime, the subcontractors on this award, and their own subcontractors.

Subaward amounts are self-reported by prime contractors to SAM.gov and appear 1 to 2 months after the work. Duplicates are removed on a best-effort basis. Totals are incomplete and not an audit. Source: USAspending.

Agency and place

Awarding and funding

Awarded by
  1. Department of Health and Human Services
  2. National Institutes Of Health
  3. NATIONAL INSTITUTES OF HEALTH NIAID
Funded by
  1. Department of Health and Human Services
  2. National Institutes Of Health
  3. NATIONAL INSTITUTES OF HEALTH NIAID
Funded from
National institute of allergy and infectious diseases (0885); Nih office of the director (0846)Program activities075-0846, 075-0885Federal accounts (agency financial reports)

Place of performance

Place of performance
Galveston, Texas 77550-1532
Congressional district (place of performance)
TX-14As reported at the time of the action

Classification and competition

Classification

Competition

Extent competed
Full and open competitionA
Solicitation procedures
Negotiated proposal/quoteNP
Set-aside
No set-aside used
Contract pricing
Cost plus fixed feeU
Offers received
29

Solicitation and notices

Solicitation ID
BAANIAIDNIHAI2015042(as reported)

Contract details

Subcontracting plan
Plan not requiredB
Major program
Igf::ot::igf TP508: a novel nuclear countermeasure targeting endothelial cells and stem cellsto comb
Cost Accounting Standards clause
Not applicable exempt from CASX
Certified cost or pricing data
No
Commercial procedures
Commercial products/services procedures not usedD
Government-furnished property
Transaction does not use GFE/GFPN
Bundled requirement
Not a bundled requirementD
Consolidated requirement
No
Undefinitized action (terms not final)
No
Multi-year contract
No
Performance-based service acquisition
No - service where PBA is not used.N

Linked notices

Notice
Notice ID
Type
Link
Posted

Transaction history

Modification history

Base award
Jan 30, 2017Base obligation at award: $1,605,375
Latest action
Apr 5, 2023 — Funding onlyModification P00017; obligation change -$0; funding only: changes obligations, not scope
Latest substantive action
Jul 28, 2020 — Supplemental agreement (within scope)Modification P00012; obligation change +$587,995
Latest funding action
Apr 5, 2023 — Funding onlyModification P00017; obligation change -$0; funding only: changes obligations, not scope
Actions by type
  • Base award1
  • Other administrative action13
  • Option exercised2
  • Supplemental agreement (within scope)1
  • Funding only1
18 actions recorded, Jan 30, 2017 to Apr 5, 2023; each action counted once.

Similar awards

PIID
Match
Awardee

All contract data

All contract data

Every other field reported for this award, as of its latest reported action

Competition

Evaluation preference
No preference used
Local area set-aside
No
Synopsized publicly (SAM.gov / FedBizOpps)
Yes
Simplified procedures for commercial items
No
A-76 (FAIR Act) action
No

Pricing and financing

Paid by purchase card
No
Latest action: change in base and exercised options
-$0
Latest action: change in base and all options
-$0

Socio-economic and policy

Inherently governmental functions
Other functionsOT
Recovered materials and sustainability
No clauses included and no sustainability includedC
EPA-designated product
Not requiredE
Clinger-Cohen Act planning (IT)
No

Place and origin

Domestic or foreign entity
U.S. owned businessA
Country of product or service origin
United statesUSA
Place of manufacture
Not a manufactured end productC

Structure

Award or IDV
Award
Award type
Definitive contractD
Awarding agency code
7500
Awarding sub-tier code
7529
Contracting office code
75N930
Transactions recorded under this award key
18

Funding

Funding agency code
7500
Funding sub-tier code
7529
Funding office code
75N930
Treasury accounts
  • 075-2017/2017-0846-000
  • 075-2018/2018-0846-000
  • 075-2019/2019-0846-000
  • 075-2020/2024-0885-000
Object classes
  • 25.5: Research and development contracts
Disaster or emergency funding (DEFC)
  • L: Emergency P.L. 116-123
  • Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression
COVID-19 supplemental obligations
$1,500,152
COVID-19 supplemental outlays
$1,500,152